Bisphosphonate Treatment and Related Agents in Children - Osteogenesis Imperfecta - page 462

level of ambulation in children with osteogenesis imperfecta.
J Pediatr 2006;148:456-60.

[60] DiMeglio LA, Peacock M. Two-year clinical trial of oral alendro-

nate versus intravenous pamidronate in children with osteogen-
esis imperfecta. J Bone Miner Res 2006;21:132-40. [41] de Graaff F, Verra W, Pruijs JE, Sakkers RJ. Decrease in outpa-

tient department visits and operative interventions due to
bisphosphonates in children with osteogenesis imperfecta.
J Child Orthop 2011;5:121-5.

[61] Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D,

Browne R, et al. Impact of alendronate on quality of life in
children with osteogenesis imperfecta. J Pediatr Orthop
2005;25:786-91. [42] Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH. The effect

of cyclical intravenous pamidronate in children and adolescents
with osteogenesis imperfecta type V. Bone 2006;38:13-20.

[62] Kok DH, Sakkers RJ, Janse AJ, Pruijs HE, Verbout AJ, Castelein

RM, et al. Quality of life in children with osteogenesis imper-
fecta treated with oral bisphosphonates (olpadronate): a
2-year randomized placebo-controlled trial. Eur J Pediatr
2007;166:1155-61.

[43] Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imper-

fecta type VI in childhood and adolescence: effects of cyclical
intravenous pamidronate treatment. Bone 2007;40:638-44.

[44] Cheung MS, Glorieux FH, Rauch F. Intravenous pamidronate in

osteogenesis imperfecta type VII. Calcif Tissue Int 2009;84:203-9.

[63] Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE,

Grogan D, et al. Alendronate for the treatment of pediatric
osteogenesis imperfecta: a randomized placebo-controlled
study. J Clin Endocrinol Metab 2011;96:355-64.

[45] Zacharin M, Bateman J. Pamidronate treatment of osteogenesis

imperfecta - lack of correlation between clinical severity, age at
onset of treatment, predicted collagen mutation and treatment
response. J Pediatr Endocrinol Metab 2002;15:163-74.

[64] Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M,

Pruijs H, et al. Skeletal effects and functional outcome with
olpadronate in children with osteogenesis imperfecta: a 2-year
randomised placebo-controlled study. Lancet 2004;363:1427-31.

[46] Rauch F, Travers R, Glorieux FH. Pamidronate in children with

osteogenesis imperfecta: histomorphometric effects of long-term
therapy. J Clin Endocrinol Metab 2006;91:511-6. [65] Rauch F, Munns CF, Land C, Cheung M, Glorieux FH.

Risedronate in the treatment of mild pediatric osteogenesis
imperfecta: a randomized placebo-controlled study. J Bone
Miner Res 2009;24:1282-9.

[47] Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L,

et al. Intravenous neridronate in children with osteogenesis
imperfecta: a randomized controlled study. J Bone Miner Res
2005;20:758-63. [66] Bishop N, Harrison R, Ahmed F, Shaw N, Eastell R,

Campbell M, et al. A randomized, controlled dose-ranging
study of risedronate in children with moderate and severe
osteogenesis imperfecta. J Bone Miner Res 2010;25:32-40.

[48] Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S,

Tato L. Early bisphosphonate treatment in infants with severe
osteogenesis imperfecta. J Pediatr 2006;149:174-9.

[49] Li M, Xia WB, Xing XP, Yu W, Hu YY, Jiang Y, et al. Beneit of

infusions with ibandronate treatment in children with osteogen-
esis imperfecta. Chin Med J (Engl) 2011;124:3049-53.

[67] Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress

with pamidronate treatment in infants with severe osteogenesis
imperfecta. Bone 2004;35:231-4.

[50] Ipach I, Kluba T, Wolf P, Pontz B, Mittag F. The inluence of

ibandronate treatment on bone density and biochemical bone
markers in patients with osteogenesis imperfecta. Orthop Rev
(Pavia) 2012;4:e29.

[68] Cheung MS, Glorieux FH, Rauch F. Large osteoclasts in pediat-

ric osteogenesis imperfecta patients receiving intravenous pami-
dronate. J Bone Miner Res 2009;24:669-74.

[69] Land C, Rauch F, Glorieux FH. Cyclical intravenous pami-

dronate treatment affects metaphyseal modeling in grow-
ing patients with osteogenesis imperfecta. J Bone Miner Res
2006;21:374-9.

[51] Munns CF, Rajab MH, Hong J, Briody J, Hogler W,

McQuade M, et al. Acute phase response and mineral status fol-
lowing low dose intravenous zoledronic acid in children. Bone
2007;41:366-70. [70] Kamoun-Goldrat A, Ginisty D, Le Merrer M. Effects of bisphos-

phonates on tooth eruption in children with osteogenesis imper-
fecta. Eur J Oral Sci 2008;116:195-8.

[52] Vuorimies I, Toiviainen-Salo S, Hero M, Makitie O. Zoledronic

acid treatment in children with osteogenesis imperfecta. Horm
Res Paediatr 2011;75:346-53. [71] Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR,

Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of
the jaw: report of a task force of the American Society for Bone
and Mineral Research. J Bone Miner Res 2007;22:1479-91.

[53] Brown JJ, Zacharin MR. Safety and eficacy of intravenous zole-

dronic acid in paediatric osteoporosis. J Pediatr Endocrinol
Metab 2009;22:55-63.

[54] Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M.

Safety and eficacy of a 1-year treatment with zoledronic acid
compared with pamidronate in children with osteogenesis
imperfecta. J Pediatr Endocrinol Metab 2012;25:485-91.

[72] Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux

FH, Rauch F. Tooth extraction socket healing in pediat-
ric patients treated with intravenous pamidronate. J Pediatr
2008;153:719-20.

[55] Akcay T, Turan S, Guran T, Bereket A. Alendronate treat-

ment in children with osteogenesis imperfecta. Indian Pediatr
2008;45:105-9.

[73] Malmgren B, Astrom E, Soderhall S. No osteonecrosis in jaws

of young patients with osteogenesis imperfecta treated with
bisphosphonates. J Oral Pathol Med 2008;37:196-200.

[56] Ward LM, Denker AE, Porras A, Shugarts S, Kline W, Travers R,

et al. Single-dose pharmacokinetics and tolerability of alendro-
nate 35- and 70-milligram tablets in children and adolescents
with osteogenesis imperfecta type I. J Clin Endocrinol Metab
2005;90:4051-6.

[74] Brown JJ, Ramalingam L, Zacharin MR. Bisphosphonate-

associated osteonecrosis of the jaw: does it occur in children?
Clin Endocrinol (Oxf) 2008;68:863-7.

[75] Maines E, Monti E, Doro F, Morandi G, Cavarzere P,

Antoniazzi F. Children and adolescents treated with neridronate
for osteogenesis imperfecta show no evidence of any osteone-
crosis of the jaw. J Bone Miner Metab 2012;30:434-8.

[57] Cho T-J, Choi IH, Chung CY, Yoo WJ, Park MS, Park YK.

Eficacy of oral alendronate in children with osteogenesis imper-
fecta. J Pediatr Orthop 2005;25:607-12. [76] Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed

osteotomy but not fracture healing in pediatric osteogenesis
imperfecta patients receiving pamidronate. J Bone Miner Res
2004;19:1779-86.

[58] Vyskocil V, Pikner R, Kutilek S. Effect of alendronate therapy

in children with osteogenesis imperfecta. Joint Bone Spine
2005;72:416-23.

[59] Madenci E, Yilmaz K, Yilmaz M, Coskun Y. Alendronate treat-

ment in osteogenesis imperfecta. J Clin Rheumatol 2006;12:53-6.

[77] Pizones J, Plotkin H, Parra-Garcia JI, Alvarez P,

Gutierrez P, Bueno A, et al. Bone healing in children with